Billings Gazette

Share

Billings Gazette

 •  August 23

Two members of the U.S. House of Representatives Committee on Oversight and Government Reform want to know why the prices of multiple sclerosis (MS) drugs are so high. Rep. Elijah Cummings (D-Md.) and Rep. Peter Welch (D-Vt.) have sent letters to seven drugmakers, including Biogen (NASDAQ: BIIB) and Teva Pharmaceutical Industries (NYSE: TEVA),...

Billings Gazette

 •  August 22

Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful treatments. Market research firm EvaluatePharma evaluated all of the experimental cancer drugs in late-stage development. The firm ranked these drugs by...

Billings Gazette

 •  August 6

If you've picked up a prescription from your local pharmacy recently, you probably don't need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation in the U.S. for some time now. Cancer drug prices are headed into the stratosphere According to Segal Consulting, prescription drugs are estimated to...

Billings Gazette

 •  July 23

You don't have to be Nostradamus to successfully predict that more states will legalize marijuana -- whether for medicinal use only or for recreational use. A bandwagon effect seems quite likely, considering 29 states plus the District of Columbia have already legalized medical marijuana. Nine of those (including D.C.) have also made recreational...

Billings Gazette

 •  July 21

A new gene therapy drug, the first in its class, was recommended for approval to the US Food and Drug Administration by an advisory committee on Wednesday. If approved by the FDA, the agency would consider it the first gene therapy to hit the market. The drug may provide a second chance to some leukemia patients whose first-line drugs have...

Billings Gazette

 •  July 16

Corcept Therapeutics (NASDAQ: CORT) is one hot biotech stock no matter how you look at it. Shares have nearly quintupled in value in just three years. So far in 2017, Corcept stock is up around 70%. Those kinds of returns could make millionaires out of some investors if the momentum continues. But is it too late to buy Corcept stock now? Here are...

Billings Gazette

 •  June 25

The U.S. Food and Drug Administration (FDA) is tasked with an inglorious job. It digs through hundreds, if not thousands, of pages of clinical trial data to determine if an experimental drug or medical device effectively reaches its treatment goal without outweighing the risks involved with taking or using it. The FDA has formally done this task...